Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multicenter Phase IV Study to Investigate the Immunogenicity of Recombinant Human Follicle-Stimulating Hormone and Its Impact on Clinical Outcomes in Females Undergoing Controlled Ovarian Stimulation.
Majumdar A, Hoang L, Loc LT, Srivastava P, Ramamurthy C, Chakravorty R, Nandanwar YS, Rashmi MD, Mayekar RV, Sridhar J, Divekar GH, John J. Majumdar A, et al. Among authors: ramamurthy c. J Hum Reprod Sci. 2019 Oct-Dec;12(4):303-309. doi: 10.4103/jhrs.JHRS_33_19. Epub 2019 Dec 17. J Hum Reprod Sci. 2019. PMID: 32038080 Free PMC article.
A new normal with cataract surgery during COVID-19 pandemic.
Reddy JC, Vaddavalli PK, Sharma N, Sachdev MS, Rajashekar YL, Sinha R, Agarwal A, Porwal A, Chakrabarti A, Nayak BK, Jain BK, Chandrasekhar D, Ramamurthy C, Mehta CK, Bhattacharya D, Luthra G, Aravind H, Bhattacharjee H, Mehta HR, Titiyal JS, Ram J, Bhalla JS, Dasari KK, Mehta KR, Kudlu KP, Prasad RK, Murugesan K, Singh MJ, Rajan M, Rohit OP, Gogate P, Biswas P, Padmanabhan P, Parekh RH, Khanna R, Honavar SG, Murthy SI, Goel S, Ganesh S, Arora VK. Reddy JC, et al. Among authors: ramamurthy c. Indian J Ophthalmol. 2020 Jul;68(7):1269-1276. doi: 10.4103/ijo.IJO_1528_20. Indian J Ophthalmol. 2020. PMID: 32587150 Free PMC article.
Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3.
Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, Agarwal N, Gupta S, Fléchon A, Ramamurthy C, Davis NB, Recio-Boiles A, Sternberg CN, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa ST, Loriot Y. Grivas P, et al. Among authors: ramamurthy c. J Clin Oncol. 2024 Apr 20;42(12):1415-1425. doi: 10.1200/JCO.22.02835. Epub 2024 Jan 23. J Clin Oncol. 2024. PMID: 38261969 Clinical Trial.
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Milowsky MI, O'Donnell PH, Hoimes CJ, Petrylak DP, Flaig TW, Moon HH, Friedlander TW, Mar N, McKay RR, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret AS, Yu Y, Dillon R, Kataria R, Beaumont JL, Purnajo I, Rosenberg JE. Milowsky MI, et al. Among authors: ramamurthy c. J Clin Oncol. 2024 Apr 20;42(12):1403-1414. doi: 10.1200/JCO.23.01547. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215355 Clinical Trial.
59 results